logo
Share SHARE
FONT-SIZE Plus   Neg

Genmab Announces First Phase III Trial Of Daratumumab - Quick Facts

Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said its partner, Janssen Biotech, Inc. would begin a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The trial would compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone.

Genmab's Chief Executive stated: "The daratumumab development program is progressing very well. We are extremely pleased to be able to announce that this study evaluating daratumumab in combination with a core multiple myeloma treatment regime will initiate patient recruitment in the coming months."

The Phase III trial would comprise nearly 500 patients with relapsed or refractory multiple myeloma. Patients would be randomized to receive either daratumumab combined with lenalidomide and dexamethasone, or lenalidomide and dexamethasone alone. The company said the study's primary endpoint is progression free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ford Motor Co. has announced a safety recall for about 680,000 vehicles, mainly in North America, to fix faulty seat belts that may not hold people in the event of a crash. The recall, primarily for mid-size sedans, includes about 650,000 Ford Fusion vehicles manufactured between 2013 and 2016 and Lincoln MKZ produced between 2013 and 2015. Apple Inc. has confirmed its interest in autonomous vehicle technology, saying it is excited about the potential of automated systems in many areas, including transportation. In a letter to the National Highway Traffic Safety Administration, Steve Kenner, Apple's director of product integrity, said that the tech giant looks forward to collaborating with the regulator and other stakeholders. Japanese electronics maker Panasonic Corp. is in talks to buy Austrian headlight manufacturer ZKW Group GmbH, Nikkei business daily reported Monday, citing a person familiar with the matter. As per the report, both companies could reach a basic agreement as early as this month for a deal that could be worth up to $1 billion.
comments powered by Disqus
Follow RTT